Quick Answer
XBiotech Inc. reported Net Income of -$45.54 million for fiscal year 2025.
XBiotech Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$45.54M -18.2% |
-$38.53M -56.9% |
-$24.56M +25.4% |
-$32.90M -88.9% |
-$17.41M -55.2% |
-$11.22M -101.7% |
| Diluted EPS | — | — | -$0.81 +25.0% |
-$1.08 -86.2% |
-$0.58 -61.1% |
-$0.36 -102.5% |
| Total Assets | $150.08M -24.6% |
$199.09M -12.1% |
$226.62M -7.9% |
$246.10M -10.6% |
$275.18M -22.2% |
$353.74M -56.7% |
| Cash and Equivalents | $125.55M -27.3% |
$172.68M -13.7% |
$200.02M +27.2% |
$157.31M -33.6% |
$236.98M -0.2% |
$237.37M -66.8% |
| Stockholders Equity | $140.35M -23.0% |
$182.27M -16.7% |
$218.85M -9.0% |
$240.40M -10.8% |
$269.38M -22.7% |
$348.64M -53.9% |
| R&D Expense | $47.39M +25.5% |
$37.76M +14.9% |
$32.85M +4.1% |
$31.54M +11.6% |
$28.27M +196.7% |
$9.53M -60.5% |
| Operating Income | -$55.69M -31.1% |
-$42.47M -13.2% |
-$37.51M -8.8% |
-$34.49M -37.5% |
-$25.08M -37.2% |
-$18.28M +41.5% |
| Gross Profit | — | — | $0.00 -100.0% |
$3.36M -73.3% |
$12.57M +33.1% |
$9.45M |
| Shares Outstanding | 30.49M +0.0% |
30.49M +0.2% |
30.44M -0.0% |
30.44M +0.0% |
30.44M +3.9% |
29.30M -29.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$6.01M | -19.8% | -242.1% |
| Total Assets | September 30, 2025 | $172.42M | -17.8% | -3.5% |
| Cash and Equivalents | September 30, 2025 | $147.37M | -19.5% | -3.6% |
| Stockholders Equity | September 30, 2025 | $167.08M | -13.0% | -3.5% |
| R&D Expense | September 30, 2025 | $5.08M | -28.7% | -4.8% |
| Operating Income | September 30, 2025 | -$6.05M | +23.5% | +4.6% |
| Gross Profit | September 30, 2023 | $0.00 | -100.0% | — |
| Shares Outstanding | September 30, 2025 | 30.49M | +0.0% | +0.0% |
- XBiotech Inc. reported Net Income of -$45.54 million for fiscal year 2025.
- XBiotech Inc. showed a decrease of -18.2% in Net Income compared to the prior fiscal year.
- XBiotech Inc. reported Diluted EPS of $0.81 per share (loss) for fiscal year 2023.
- XBiotech Inc. showed an increase of +25.0% in Diluted EPS compared to the prior fiscal year.
- XBiotech Inc. reported Total Assets of $150.08 million for fiscal year 2025.
- XBiotech Inc. showed a decrease of -24.6% in Total Assets compared to the prior fiscal year.
- XBiotech Inc. reported Cash and Equivalents of $125.55 million for fiscal year 2025.
- XBiotech Inc. showed a decrease of -27.3% in Cash and Equivalents compared to the prior fiscal year.
- XBiotech Inc. reported Stockholders Equity of $140.35 million for fiscal year 2025.
- XBiotech Inc. showed a decrease of -23.0% in Stockholders Equity compared to the prior fiscal year.
- XBiotech Inc. reported R&D Expense of $47.39 million for fiscal year 2025.
- XBiotech Inc. showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- XBiotech Inc. reported Operating Income of -$55.69 million for fiscal year 2025.
- XBiotech Inc. showed a decrease of -31.1% in Operating Income compared to the prior fiscal year.
- XBiotech Inc. reported Gross Profit of $0.00 for fiscal year 2023.
- XBiotech Inc. showed a decrease of -100.0% in Gross Profit compared to the prior fiscal year.
- XBiotech Inc. reported Shares Outstanding of 30.49 million shares for fiscal year 2025.
- XBiotech Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: